Analyst Price Targets — EVAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 12:42 pm | — | Lake Street | $9.00 | $3.08 | TheFly | Evaxion Biotech price target lowered to $9 from $11 at Lake Street |
| February 19, 2026 1:21 pm | — | Maxim Group | $10.00 | $3.25 | TheFly | Evaxion Biotech initiated with a Buy at Maxim |
| October 20, 2025 12:43 pm | Thomas Flaten | Lake Street | $11.00 | $7.14 | TheFly | Evaxion Biotech price target raised to $11 from $6 at Lake Street |
| September 25, 2025 3:18 pm | — | H.C. Wainwright | $16.00 | $4.53 | TheFly | Evaxion Biotech price target raised to $16 from $14 at H.C. Wainwright |
Latest News for EVAX
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026 to be held in Madrid, Spain, from October 23-27,…
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new preclinical data for vaccine candidate EVX-V1 in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15, 2026.
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EVAX.
U.S. House Trading
No House trades found for EVAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.